NASDAQ · ALLO
Allogene Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ALLO: Nov 5, 2026
Allogene Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.13 | $-0.09 | $-0.15 | 4 |
| Dec 2026 | $-0.14 | $-0.12 | $-0.15 | 4 |
| Mar 2027 | $-0.14 | $-0.13 | $-0.15 | 2 |
| Jun 2027 | $-0.14 | $-0.13 | $-0.15 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Sep 11, 11:30 AM EDTAllogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- RTTNews · Sep 2, 9:59 AM EDTAllogene's Executive VP & CFO Geoffrey Parker To Retire(RTTNews) – Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company, announced Wednesday the retirement of Geoffrey Parker, Executive Vice President and Chief Financial Officer (CFO), effective November 6, 2026.
- The Motley Fool · Aug 19, 4:58 PM EDTAllogene (ALLO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 17, 9:40 AM EDTIs Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
- Zacks · Aug 13, 1:47 PM EDTAllogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D CostsALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
- MarketBeat · Aug 12, 6:04 PM EDTAllogene Therapeutics Q2 Earnings Call Highlights3 Stocks With Sky-High Short Interest LevelsAllogene Therapeutics (NASDAQ:ALLO) outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designa
- RTTNews · Jul 30, 4:56 AM EDTFDA Grants RMAT, Fast Track Status To Cema-cel For High-Risk Large B-cell Lymphoma; Stock Up(RTTNews) – Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company, announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to cemacabtagene ansegedleucel, or cema-cel, in Large B-Cell Lymphoma, support
- Zacks · Jun 12, 11:30 AM EDTWhy Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · May 14, 10:17 AM EDTAllogene Therapeutics Posts Narrower-Than-Expected Loss in Q1ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
- MarketBeat · May 13, 8:13 PM EDTAllogene Therapeutics Q1 Earnings Call Highlights3 Stocks With Sky-High Short Interest LevelsAllogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing. On the company’s quarterly c
- The Motley Fool · May 13, 6:38 PM EDTAllogene (ALLO) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Apr 28, 11:37 AM EDTAllogene Therapeutics (ALLO) Price Target Increased by 16.66% to 8.83The average one-year price target for Allogene Therapeutics (NasdaqGS:ALLO) has been revised to $8.83 / share. This is an increase of 16.66% from the prior estimate of $7.57 dated April 12, 2026. The price target is an average of many targets provided by analy
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Allogene Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.